Journal of Thrombosis and Thrombolysis

, Volume 35, Issue 3, pp 304–311 | Cite as

Impact of target-specific oral anticoagulants on transitions of care and outpatient care models

CME/CNE Article

Abstract

Patients with acute or chronic illness experience transitions of care when they leave one healthcare setting and move to another. Care transitions are points of increased patient risk. Numerous care transition models have been developed that focus on improving the hospital discharge process to prevent adverse events after hospital discharge and to reduce readmission rates. Anticoagulants are a common cause of adverse drug events in hospitals, and of adverse events that lead to patient harm and hospital readmission. Anticoagulation management services improve the outcomes of anticoagulant therapy in both hospitalized and ambulatory patients. The services they provide, including improved communication, medication management, and patient education, are also central tenets of care transition models. These services have traditionally been focused around warfarin and heparin. Recently, new target specific oral anticoagulants have been approved in the US for various indications that traditionally have been treated with warfarin. These new agents are administered in fixed doses without the need for routine laboratory monitoring or frequent dosing adjustments. Yet as high risk drugs, they will require systematic efforts to assure their safety and minimize potential adverse events. These concerns are of particular importance during transitions of care. Anticoagulation management services, must be prepared to establish practices that improve patient outcomes regardless of the anticoagulant prescribed, using the established principals of care transition models.

Keywords

Anticoagulation Dabigatran Rivaroxaban Apixaban Transition of care Anticoagulation clinic 

References

  1. 1.
    Adam SS, McDuffie JR et al (2012) Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med. doi: 10.7326/0003-4819-157-10-201211200-00532 PubMedGoogle Scholar
  2. 2.
    National Transitions of Care Coalition. Improving transitions of care: the vision of the National Transition of Care Coalition. http:/www.ntocc.org/portals/0/policypaper.pdf. Accessed 28 Dec, 2012
  3. 3.
    Centers for Disease Control and Prevention. National Hospital Discharge Survey 2010. http://www.cdc.gov/nchs/nhds.htm. Accessed 28 Dec, 2012
  4. 4.
    Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project 2009. http://www.hcup-us.ahrq.gov/reports/factsandfigures/2009/TOC_2009.jsp. Accessed 28 Dec, 2012
  5. 5.
    Moore C, Wisnivesky J, Williams S, McGinn T (2003) Medical errors related to discontinuity of care from and inpatient to an outpatient setting. J Gen Intern Med 18:646–651PubMedCrossRefGoogle Scholar
  6. 6.
    Forster AJ, Murff HJ, Peterson JF, Chandi TK, Bates DW (2003) The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med 138:161–167PubMedGoogle Scholar
  7. 7.
    Boockvar K, Fishman E, Kyriacou CK, Monias A, Gavi S, Cortes T (2004) Adverse events due to discontinuations in durg use and dose changes in patients transferred between acute and long term care facilities. Arch Intern Med 164:545–550PubMedCrossRefGoogle Scholar
  8. 8.
    Gray SL, Mahoney JE, Blough DK (1999) Adverse drug events in elderly patients receiving home health services following hospital discharge. Ann Pharmaoctherapy 33:1147–1153CrossRefGoogle Scholar
  9. 9.
    Rozich J, Resar R (2001) Medication safety: one organization’s aproach to the challenge. J Clin Outcomes Manag 8:27–34Google Scholar
  10. 10.
    Jencks SF, Williams MV, Coleman EA (2009) Rehospitalizations among patients in the Medicare Fee-for-Service program. New Engl J Med 360:1418–1428PubMedCrossRefGoogle Scholar
  11. 11.
    Center for Medicare and Medicaid Services. Readmissions reduction program. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program.html. Accessed December 28, 2012
  12. 12.
    Jack BW, Chetty VK, Anthony D, Greenwald JL, Sanchez GM et al (2009) A reengineered hospital discharge program to decrease rehospitalization. Ann Intern Med 150:178–187PubMedGoogle Scholar
  13. 13.
    Coleman EA, Parry C, Chalmers S, Min Sung-joon (2006) The care transitions intervention. Results of a randomized controlled trial. Arch Intern Med 166:1822–1828PubMedCrossRefGoogle Scholar
  14. 14.
    Naylor MD, Brooten D, Campbell R, Jocbsen BS, Mezey MD et al (1999) Comprehensive discharge planning and home followup of hospitalized elders. A randomized controlled trial. JAMA 281:613–620Google Scholar
  15. 15.
    Boult C, Reider L, Leff B, Frick KD, Boyd CM, Wolff JL et al (2011) The effect of guided care teams on the use of health services. Results from a cluster-randomized controlled trial. Arch Intern Med 171:460–466PubMedCrossRefGoogle Scholar
  16. 16.
    Bradley EH, Curry L, Horwitz LI, Sipsma H, Thompson JW et al (2012) Contemporary evidence about hospital strategies for reducing 30-day readmissions. A national study. J Am Coll Cardiol 60:607–614PubMedCrossRefGoogle Scholar
  17. 17.
    Hansen LO, Young RS, Hinami K, Leung A, Williams MV (2011) Interventions to reduce 30-day rehospitalization: a systematic review. Ann Intern Med 155:520–528PubMedGoogle Scholar
  18. 18.
    Snow V, Beck D, Budnitz T, Miller DC, Potter J et al (2009) Transitions of care consensus policy statement. J Hosp Med 4:364–370PubMedCrossRefGoogle Scholar
  19. 19.
    The Joint Commission. National Patient Safety Goals 2013. http://www.jointcommission.org/assets/1/18/NPSG_Chapter_Jan2013_HAP.pdf. Accessed 28 Dec, 2012
  20. 20.
    APhA, ASHP, Steeb D, Webster L (2012) Improving care transitions: optimizing medication reconciliation. J Am Pharm Assoc 52:e43–e52CrossRefGoogle Scholar
  21. 21.
    Classen DC, Jaser L, Budnitz DS (2010) Adverse drug events among hospitalized Medicare patients: epidemiology and national estimates from a new approach to surveillance. Jt Comm J Qual Patient Saf 36:12–21PubMedGoogle Scholar
  22. 22.
    Piazza G, Nguyen TN, Cios D, Labreche M, Hohlfelder B et al (2011) Anticoagulation-associated adverse drugeents. Am J Med 124:1136–1142PubMedCrossRefGoogle Scholar
  23. 23.
    Hafner JW, Belknap SM, Squillante MD, Bucheit KA (2002) Adverse drug events in emergency department patients. Ann Emerg Med 39:258–267PubMedCrossRefGoogle Scholar
  24. 24.
    Budnitz DS, Pollock DA, Mendelsohn AB, Weidenback KN, McDonald AK, Annest JL (2005) Emergency department visits for outpatient adverse drug events: demonstration for a national surveillance system. Ann Emerg Med 45:197–206PubMedCrossRefGoogle Scholar
  25. 25.
    Budnitz DS, Lovegrove MC, Shehab N, Richards CL (2011) Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 365:2002–2012PubMedCrossRefGoogle Scholar
  26. 26.
    Shehab N, Sperling LS, Kegler SR, Budnitz DS (2010) National estimates of emergency department visits for hemorrhage related adverse events from clopidogrel plus aspirin and from warfarin. Arch Intern Med 170:1926–1933PubMedCrossRefGoogle Scholar
  27. 27.
    Institute of Safe Medication Practices. high alert medications list. http://www.ismp.org/Tools/highAlertMedicationLists.asp. Accessed 28 Dec, 2012
  28. 28.
    Nutescu EA, Wittkowsky AK, Burnett A, Merli G (2013) Consensus guidelines for inpatient management of anticoagulant therapy: from the anticoagulation forum. Ann Pharmacotherapy (in press)Google Scholar
  29. 29.
    Kucukarslan SN, Peters M, Mlynarek M, Nafziger DA (2003) Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Intern Med 163:2014–2018PubMedCrossRefGoogle Scholar
  30. 30.
    Dager WE, Gulseth MP (2007) Implementing anticoagulation management by pharmacists in the inpatient setting. Am J Health Syst Pharm 64:1071–1079PubMedCrossRefGoogle Scholar
  31. 31.
    Burnett A, D’Angio R, Earl LE, Garcia D (2011) Challenges and benefits of an inpatient anticoagulation service: one hospital’s experience. J Thromb Thrombolysis 31:344–352PubMedCrossRefGoogle Scholar
  32. 32.
    Jennings HR, Miller EC, Williams TS, Tichenor SS, Woods EA (2008) Reducing anticoagulation medication adverse events and avoidable patient harm. Jt Comm J Qual Patient Saf 34:196–200PubMedGoogle Scholar
  33. 33.
    Bond CA, Raehl CL (2004) Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions. Pharmacotherapy. 24:953–963PubMedCrossRefGoogle Scholar
  34. 34.
    Holbrook A, Schulman S, Witt DM, Vandvick PO, Fish J et al (2012) Evidence-based management of anticoagulant therapy antithrombotic therapy and prevention of thrombosis 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(suppl):e152s–e184sPubMedCrossRefGoogle Scholar
  35. 35.
    Schillig J, Kaatz S, Hudson M, Krol GD, Szandik EG, Kalus J (2011) Clinical and safety impact of an inpatient pharmacist-directed anticoagulation service. J Hosp Med 6:322–328PubMedCrossRefGoogle Scholar
  36. 36.
    Pernod G, Labarere J, Yver J et al (2008) EDU’AVK: reduction of oral anticoagulant related adverse events after patient education: a prosepective multicenter open randomized study. J Gen Intern Med 23:1441–1446PubMedCrossRefGoogle Scholar
  37. 37.
    Tang EO, Lai CS, Lee KK et al (2003) Relationship between patients’ warfarin knowledge and anticoagulant control. Ann Pharmacother 37:34–39PubMedCrossRefGoogle Scholar
  38. 38.
    Wilhelm SM, Petrovitch EA (2011) Implementation of an inpatient anticoagulation teaching service: expanding the role of pharmacy students and residents in patient education. Am J Health Syst Pharm 68:2086–2093PubMedCrossRefGoogle Scholar
  39. 39.
    Nutescu EA, Spinler SA, Dager WE, Bussey HI (2004) Transitioning from traditional to novel anticoagulants: the impact of oral direct thrombin inhibitors on anticoagulation management. Pharmacotherapy 24(10 pt 2):199–202sCrossRefGoogle Scholar
  40. 40.
    Gulseth MP, Wittkowsky AK, Fanikos J, Spinler SA, Dager WE, Nutescu EA (2011) Dabigatran etexilate in clinical practice. Confronting challenges to improve safety and effectiveness. Pharmacotherapy 31:1232–1249PubMedCrossRefGoogle Scholar
  41. 41.
    US Food and Drug Administration. Medication Guides. http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm. Accessed 28 Dec, 2012
  42. 42.
    Spinler SA, Willey VJ (2011) A patient’s guide to taking dabigatran etexilate. Circulation 124:e209–e211PubMedCrossRefGoogle Scholar
  43. 43.
    Cios D, Fanikos J (2012) Rivaroxaban to prevent pulmonary embolism after hip or knee replacement. Circulation 125:e542–e544PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Anticoagulation ServicesUniversity of Washington Medical CenterSeattleUSA
  2. 2.University of Washington School of PharmacySeattleUSA

Personalised recommendations